Abstracts tagged "hyperuricemia"

Abstract Number: 1652 • ACR Convergence 2025
The Hidden Impact of Hyperuricemia on Immune Cell Dysfunction
Isabella Yi, Henry Ping and Qian Wang, iLab Research Institute, Mountain View, CA
Background/Purpose: Background: Hyperuricemia, characterized by elevated serum uric acid levels, is often asymptomatic yet poses serious health risks. This study investigates how soluble monosodium urate…
Abstract Number: 1133 • ACR Convergence 2025
A Proteomic Analysis Of Subclinical Synovial Inflammation Associated With Monosodium Urate Crystal Deposition
Mariano Andrés¹, María-Luisa Peral-Garrido², Samanta Ortuño³, Rocío Caño³, Silvia Gómez-Sabater³, Alejandra Bermúdez⁴, Teresa Lozano⁵, Miguel Perdiguero⁵, elena Caro-Martínez⁶, Ruth Sánchez-Ortiga⁵, Carolina Ruiz-García⁷, Eliseo Pascual⁸ and Rubén Francés⁸, ¹Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ²Vinalopó University Hospital, Novelda, Spain, ³Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, ⁴Rheumatology Department, Dr. Balmis General University Hospital, Alicante, Spain., Alicante, Spain, ⁵Dr Balmis General University Hospital, Alicante, Spain, ⁶HACLE San Vicente Hospital, San Vicente del Raspeig, Spain, ⁷Campoamor Health Center, Alicante, Spain, ⁸Miguel Hernandez University of Elche, Alicante, Spain
Background/Purpose: Persistent subclinical inflammation from monosodium urate (MSU) crystals is present in gout and asymptomatic hyperuricemia (AH). The underlying mechanism is poorly understood. This study…
Abstract Number: 1130 • ACR Convergence 2025
Novel Anti-Obesity Medications and Serum Urate Change Among Patients with Gout and Baseline Hyperuricemia
Kiara Tan¹, Jiaqi Wang¹, Saiajay Chigurupati², Gregory Challener³, Natalie McCormick¹, Sharan Rai⁴, Florence Porterfield⁵, Chika Anekwe¹, Dong Wook Kim⁶, Fatima Stanford⁷, Caroline Apovian⁸, Hyon K. Choi⁹ and Chio Yokose¹⁰, ¹Massachusetts General Hospital, Boston, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ⁴Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁵Division of Endocrinology, Massachusetts General Hospital, Boston, ⁶Division of Endocrinology, Diabetes and Hypertension, Brigham and Women’s Hospital, Boston, ⁷Neuroendocrine Unit, Pediatric Endocrinology, Massachusetts General Hospital, Boston, ⁸Brigham and Women's Hospital, Boston, ⁹MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ¹⁰Massachusetts General Hospital, Waltham, MA
Background/Purpose: Obesity affects >50% of individuals with gout and is the most important modifiable risk factor for gout. Thus, novel anti-obesity medications (AOM, e.g., semaglutide…
Abstract Number: 1129 • ACR Convergence 2025
Effectiveness of sodium-glucose cotransporter type 2 inhibitors and urate-lowering agents in patients with gout: data from a single-center specialised clinic
Jose Doménech Serrano¹, Ivana García Loiseau², Cristina RodrÍguez-Alvear³, Pablo Riesgo Sanchis¹, Oscar Moreno Pérez¹ and Mariano Andrés¹, ¹Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ²Miguel Hernández University, Alicante, Spain, ³Virgen de la Peña General Hospital, Fuerteventura, Spain
Background/Purpose: Sodium-glucose cotransporter type 2 inhibitors (SGLT2I) proved substantial benefits in diabetes mellitus (DM), heart failure (HF) and kidney disease (KD). In pivotal trials, SGLT2Is…
Abstract Number: 1124 • ACR Convergence 2025
ABCG2 Variants as Genetic Risk Factors for Hyperuricemia and Gout: Focus on Pediatric and Familial Manifestations
Blanka Stiburkova¹, katerina pavelcova², Jana masinova³, Pavel Jesina⁴, Yu Toyoda⁵ and Tappei Takada⁵, ¹Institute of Rheumatology, Praha ¹⁰, Czech Republic, ²Institute of Rheumatology, Praha ², Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic, ⁴Revmatologický ústav, Praha ², Czech Republic, ⁵The University of Tokyo Hospital, Tokyo, Japan
Background/Purpose: Gout, a condition arising from hyperuricemia, is considered as both a metabolic disorder and an autoinflammatory disease. Genetic factors are estimated to contribute approximately…
Abstract Number: 1123 • ACR Convergence 2025
Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates Long Term Efficacy and Safety in Patients with Uncontrolled Gout: Results from the 24-week Double-blind Extension of the Phase 3 DISSOLVE I Study
Alan Kivitz¹, Atul Singhal², Anand Patel³, Rehan Azeem⁴, Ben Peace⁵, Bhavisha Desai⁶ and Herbert Baraf⁷, ¹Altoona Center for Clinical Research, Duncansville, PA, ²SouthWest Arthritis Research Group, Mesquite, TX, ³Conquest Research, Winter Park, FL, USA, Winter Park, FL, ⁴Global MACD, Sobi Inc., Waltham, MA, ⁵Statistical Science, Sobi, Stockholm, Sweden, ⁶Sobi, Glastonbury, CT, ⁷The Center for Rheumatology and Bone Research, Rheumatology, Wheaton, Maryland, USA; Division of Rheumatology, The George Washington University, Washington, DC
Background/Purpose: Uncontrolled gout (UG) occurs when serum uric acid (sUA) levels remain persistently elevated despite use of oral urate-lowering therapies and can result in progressively…
Abstract Number: 0171 • ACR Convergence 2025
The Association Between Short-Term Trajectory Of Atmospheric Particulate Matter 10 (PM10) Concentration And Hyperuricemia
Sunggun Lee¹, Minyoung Her¹, Seong-HO Kim¹, Yong-Gil Kim² and Ji Seon Oh², ¹Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, Seoul, Republic of Korea
Background/Purpose: The association between high atmospheric particulate matter concentration and gout flare has been reported1, but the causality and mechanism of this association remain unknown.…
Abstract Number: 2660 • ACR Convergence 2025
Understanding Gout in Women: Longitudinal Changes in Serum Urate Levels from Pre-menopause through Post-menopause
Shreya Billa¹, Sho Fukui¹, Misti Paudel², Takahiro Suzuki³, Ryosuke Imai⁴, Yuntae Kim⁵, Takehiro Nakai⁶, Hiromichi Tamaki⁶, mitsumasa kishimoto⁷, Hilde Ørbo¹, Sara Tedeschi¹, Hyon K. Choi⁸, Masato Okada⁹ and Daniel Solomon¹, ¹Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ³Department of Cardiovascular Medicine, St. Luke's International Hospital, Tokyo, Japan, ⁴Department of Pulmonary Medicine, St. Luke's International Hospital, Tokyo, Japan, ⁵Department of Gastroenterology, St. Luke's International Hospital, Tokyo, Japan, ⁶Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, ⁷Kyorin University School of Medicine, Tokyo, Japan, ⁸MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Understanding longitudinal changes in serum urate (SU) allows for the development of evidence-based interventions for gout. Post-menopausal women, who are at risk of gout,…
Abstract Number: 2590 • ACR Convergence 2025
Translating findings on urate-metabolizing bacterial genes and urate levels at the human population level: a gut microbiome analysis of three independent cohorts of men and women
Sharan Rai¹, Natalie McCormick², Xochitl Morgan³, Matthew Nayor⁴, Robert Terkeltaub⁵, Dylan Dodd⁶, Lama Nazzal⁷, Huilin Li⁷, Gary Curhan⁸, Curtis Huttenhower³ and Hyon K. Choi⁹, ¹Massachusetts General Hospital/Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Harvard T.H. Chan School of Public Health, Boston, ⁴Boston University, Boston, ⁵Retired, San Diego, CA, ⁶Stanford University, Palo Alto, CA, ⁷NYU Langone, New York, NY, ⁸Brigham and Women's Hospital, Boston, ⁹MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Approximately 21% of US adults have hyperuricemia, the causal precursor for gout. Human cells do not degrade urate (due to uricase gene inactivation). However,…
Abstract Number: 2587 • ACR Convergence 2025
Nanoencapsulated Sirolimus Plus Pegadricase Reduced Disease Burden in Patients With Uncontrolled Gout: Results From the Phase 3 DISSOLVE Trials
Puja Khanna¹, Amar Majjhoo², Rehan Azeem³, Ben Peace⁴, Bhavisha Desai⁵ and Vibeke Strand⁶, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Shores Rheumatology, St. Clair Shores, MI, ³Global MACD, Sobi Inc., Waltham, MA, ⁴Statistical Science, Sobi, Stockholm, Sweden, ⁵Sobi, Glastonbury, CT, ⁶Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Patients (pts) with uncontrolled gout (UG; persistent elevation in serum uric acid [sUA] levels and clinical manifestations despite oral urate-lowering therapy) have poor health-related…
Abstract Number: 2588 • ACR Convergence 2025
Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates a Reduction in Gout Flares: Results from the Phase 3 DISSOLVE Studies
Angelo Gaffo¹, Herbert Baraf², Anand Patel³, Tuhina Neogi⁴, Rehan Azeem⁵, Wesley DeHaan⁶, Ben Peace⁷, Hugues Santin-Janin⁸, Bhavisha Desai⁹ and Naomi Schlesinger¹⁰, ¹Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ²The Center for Rheumatology and Bone Research, Rheumatology, Wheaton, Maryland, USA; Division of Rheumatology, The George Washington University, Washington, DC, ³Conquest Research, Winter Park, FL, USA, Winter Park, FL, ⁴Boston University School of Medicine, Boston, MA, ⁵Global MACD, Sobi Inc., Waltham, MA, ⁶Sobi, Inc, Waltham, MA, ⁷Statistical Science, Sobi, Stockholm, Sweden, ⁸Sobi, BASEL, Switzerland, ⁹Sobi, Glastonbury, CT, ¹⁰Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA, Salt Lake City, UT
Background/Purpose: Urate-lowering therapy is recommended to lower serum urate (sUA) and for long-term prevention of gout flares (FitzGerald et al. Arthritis Care Res (Hoboken) 2020;…
Abstract Number: 2013 • ACR Convergence 2025
Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with Limited Treatment Options: A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase III Trial
Yu Xue¹, Tianshu Chu², Jiankang Hu³, Wei Gou⁴, Ning Zhang⁵, Juan Li⁶, Jing Yu⁷, Rongping Li⁸, Rongbin Li⁹, Long Qian¹⁰, Xinwang Duan¹¹, Lihua Duan¹² and Hejian Zou¹, ¹Department of Rheumatology,Huashan Hospital, Fudan University, Shanghai, China, shanghai, China (People's Republic), ²Department of Rheumatology, Henan Provincial People's Hospital, Zhengzhou, China, zhengzhou, China (People's Republic), ³Department of Rheumatology, Pingxiang People's Hospital, Pingxiang,China,, Pingxiang, China (People's Republic), ⁴Department of Rheumatology, Hebei Petro ChinaCentral Hospital, Langfang, China, Langfang, China (People's Republic), ⁵Department of Rheumatology, Shengjing Hospital of China Medical University, Shenyang, China, Shengjing, China (People's Republic), ⁶The First Affiliated Hospital of Hainan Medical University, Haikou, China (People's Republic), ⁷Department of Rheumatology, The FirstAffiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China, Shenyang, China (People's Republic), ⁸Department of Rheumatology, The First Affiliated Hospital of GannanMedical University, Ganzhou, China, Ganzhou, China (People's Republic), ⁹Department ofRheumatology, The First Hospital of Qiqihar, Qiqihar, China, Qiqihar, China (People's Republic), ¹⁰Department of Rheumatology, The Second Hopital of Anhui Medical University, Hefei, China, Hefei, China (People's Republic), ¹¹The Second Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ¹²Department of Rheumatology, Jiangxi Provincial People's Hospital, Nanchang, China, Nanchang, China (People's Republic)
Background/Purpose: Acute gouty arthritis(GA) is a common and debilitating condition, especially for patients unsuitable for standard therapy. Firsekibart, previously called Genakumab, is a first-in-class fully…
Abstract Number: 2000 • ACR Convergence 2025
Can Uric Acid Protect Joints? Lower Incidence of Large Joint Replacements Among Individuals with Higher SUA
Janis Timsans¹, Raine Tiihonen², Jenni Kauppi³, Vappu Rantalaiho⁴, Anne Kerola¹, Kia Hakkarainen⁵, Tiina Lehto⁶, Hannu Kautiainen⁷ and Markku Kauppi¹, ¹Päijät-Häme Central Hospital, Department of Rheumatology, Lahti, Finland, ²Päijät-Häme Central Hospital, Department of Orthopedics and Traumatology, Lahti, Finland, ³Päijät-Häme Central Hospital, Unit of Physiatry and rehabilitation medicine, Lahti, Finland, ⁴Tampere University, Faculty of Medicine and Health Technology; Tampere University Hospital, Centre for Rheumatic Diseases, Tampere, Finland, ⁵Päijät-Häme Central Hospital, Department of Nephrology, Lahti, Finland, ⁶Fimlab Laboratoriot Oy, Department of Clinical Chemistry, Lahti, Finland, ⁷Folkhälsan Research Center, Helsinki, Finland
Background/Purpose: Serum uric acid (SUA) has been linked to various health conditions, including osteoarthritis (OA), though findings have been inconsistent. Data on the relationship between…
Abstract Number: 1999 • ACR Convergence 2025
Characterization of Infusion Reactions Within 1 Hour of Treatment With Nanoencapsulated Sirolimus Plus Pegadricase: Pooled Results From the Phase 3 DISSOLVE I and DISSOLVE II Trials
Herbert Baraf¹, Andrew J. Sulich², Guillermo J. Valenzuela³, Rehan Azeem⁴, Ben Peace⁵, Bhavisha Desai⁶ and Puja Khanna⁷, ¹The Center for Rheumatology and Bone Research, Rheumatology, Wheaton, Maryland, USA; Division of Rheumatology, The George Washington University, Washington, DC, ²Shores Rheumatology, St. Clair Shores, MI, ³Iris Rheumatology, Plantation, FL, ⁴Global MACD, Sobi Inc., Waltham, MA, ⁵Statistical Science, Sobi, Stockholm, Sweden, ⁶Sobi, Glastonbury, CT, ⁷Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Uricase-based therapies may profoundly lower serum uric acid (sUA) in patients (pts) with uncontrolled gout (UG) but often lead to anti-drug antibody (ADA) formation,…
Abstract Number: 1998 • ACR Convergence 2025
Reduction in Tophi Observed in Patients with Uncontrolled Gout Treated with NASP: Results from Phase 3 DISSOLVE Studies
Herbert Baraf¹, Puja Khanna², Frédéric Lioté³, Rehan Azeem⁴, Wesley DeHaan⁵, Ben Peace⁶, Hugues Santin-Janin⁷, Bhavisha Desai⁸ and Alan Kivitz⁹, ¹The Center for Rheumatology and Bone Research, Rheumatology, Wheaton, Maryland, USA; Division of Rheumatology, The George Washington University, Washington, DC, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Université Paris Cité-Inserm UMR¹¹³² & Rheumatology Department, GH Paris Saint Joseph & Institut Arthur Vernes, Paris, France, ⁴Global MACD, Sobi Inc., Waltham, MA, ⁵Sobi, Inc, Waltham, MA, ⁶Statistical Science, Sobi, Stockholm, Sweden, ⁷Sobi, BASEL, Switzerland, ⁸Sobi, Glastonbury, CT, ⁹Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Patients (pts) with uncontrolled gout (UG) and tophi experience joint pain, impaired function and poor quality of life (Schlesinger et al. Semin Arthritis Rheum…

1
2
3
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].